Photocure ASA (OSL:PHO) to Release Q2 2008 Earnings August 15, 2008

Photocure AS A(OSL:PHO) will release the second quarter earnings for 2008 on Friday, August 15.  The financial results will be posted on the company’s investor relations website at photocure.no/Investors.

Photocure ASA is a Norway-based pharmaceutical company that develops and sells pharmaceuticals and medical devices based on its photodynamic technology, which is used to detect and cure diseases.

The Company targets the dermatology and oncology markets. Its main products comprise: Metvix, which is used for the treatment of skin cancer and pre-cancerous skin lesions; Aktilite CL 16 and CL 128, which are lamps used in photodynamic therapy (PDT) in combination with Metvix, and Hexvix, which is utilized for the detection of bladder cancer. The Company also develops photochemical internalization (PCI), a technology for light-directed drug delivery specifically into diseased cells.

Photocure ASA operates through two subsidiaries PCI Biotech Holding ASA and PCI Biotech AS, and is active in Norway, Sweden, Denmark and Finland. The Company is headquartered in Oslo, Norway.

Read more Business News on The Global Market Directory.

About The Global Market Directory (TheGMD)

TheGMD provides an online global directory listing featuring public companies, stock brokers, brokerage firms and individuals.  The GMD provides profiles for Brokerage Firms, Stock Brokers and Individuals in addition to Public Companies.

The GMD is a division of TransWorldNews, Inc. Companies can utilize the TransWorldNews press release distribution services and have all news releases attached to their GMD profile.

Create your profile on The Global Market Directory.